AseBio

#NewAseBioMember | “AseBio seeks to generate a high-added-value, and sustainable, productive framework that becomes one of the pillars of the Spanish GDP”

Meet Savana, our new member. We talked to its Antonio Urda, chief government affairs officer.

Antonio_Urda_Savana
AseBio
Corporate

AseBio. What does your company's work bring to the table and what is its strength?

Antonio Urda. Savana has established itself as one of the most innovative and robust companies globally in the field of healthcare data management, natural language processing in healthcare, and the development and implementation of artificial intelligence applied to medicine. With a 10-year history, and international presence within twelve countries, Savana has revolutionized the healthcare sector, introducing a new paradigm of efficiency, precision, and ethics in the treatment of clinical data. The key differentiator lies in providing scientifically and medically graded data, in other words, ready for management, research, or educational decisions.

AseBio. What is AseBio for you?

Antonio Urda. The leading association for the defense of the biotechnological sector. We have always believed that AseBio seeks to generate a high-added-value, and sustainable, productive framework that becomes one of the pillars of the Spanish GDP.

AseBio. When did you first hear about AseBio?

Antonio Urda. Since its foundation, when the sector was practically non-existent, AseBio has contributed not only to the creation of a sector with its own awareness but also to its strengthening as a national strategy.

AseBio. What do you expect from being part of an association like AseBio?

Antonio Urda. Being associated with AseBio, we expect will provide us access to collaboration networks with companies in the sector, allowing us to address common challenges in the field of biotechnology. Additionally, we expect that the association will facilitate the representation of the sector before governmental bodies and other institutions, thus contributing to the development and strengthening of the biotechnological industry in Spain.

AseBio. What is the biggest challenge facing the biotech sector (or your company)?

Antonio Urda. The existence of mechanisms that facilitate the development of biotechnological products and services based on artificial intelligence without violating the high standards demanded by our environment. In a competitive environment like the current one, European companies must take advantage of the framework in which we operate, rather than it being a hindrance.